Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma (Q36788503)

16 August 2017

1 reference

title

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma (English)

1 reference

16 August 2017

0 references

Paul G Richardson

1 reference

16 August 2017

Kenneth C Anderson

1 reference

16 August 2017

Dharminder Chauhan

1 reference

16 August 2017

Klaus Podar

1 reference

16 August 2017

language of work or name

1 reference

1 April 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

551-566

1 reference

Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Interleukin 6 induces the expression of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Expression of Protein Tyrosine Kinases in Islet Cells: Possible Role of the Flk-1 Receptor forβ-Cell Maturation from Duct Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The microenvironment of the tumour-host interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Galectin-3 induces endothelial cell morphogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vasculogenic mimicry and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Can mosaic tumor vessels facilitate molecular diagnosis of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Circulating endothelial precursors: mystery, reality, and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Specialization of tumour vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Endothelial cells in the bone marrow of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

A complex linkage in the developmental pathway of endothelial and hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

VEGF-A165 augments erythropoietic development from human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The PDGF/VEGF receptor controls blood cell survival in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor and its receptors in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Lysophosphatidic acid: G-protein signalling and cellular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Metronomic scheduling: the future of chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

Prognostic value of angiogenesis in solitary bone plasmacytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.551

21 January 2018

Identifiers

DOI

10.1586/14737140.7.4.551

1 reference

16 August 2017

1 reference